Results 1 to 10 of about 14,850 (194)

Cardioprotective effects of dapagliflozin against doxorubicin-induced cardiotoxicity in breast cancer patients with type 2 diabetes: a prospective study [PDF]

BMC Cancer
Aim This study aimed to evaluate the risk of doxorubicin-induced cardiotoxicity in newly diagnosed breast cancer patients with type 2 diabetes receiving dapagliflozin in addition to metformin, using echocardiographic methods, and to investigate the ...
Huseyin Ali Ozturk, Mevlut Koc, Ramazan Azim Okyay, Dilan Damla Ozturk, Erdinc Gulumsek, Mahmut Buyuksimsek, Mehmet Turker, Abdullah Eren Cetin, Fatih Necip Arici, Hilmi Erdem Sumbul   +9 more
doaj   +2 more sources

Dapagliflozin alleviates sunitinib-induced cardiotoxicity through AMPKα-PPARα axis and enhances the sensitivity of renal cell carcinoma to sunitinib [PDF]

BMC Medicine
Background Sunitinib is an orally administered novel multi-targeted therapy for treating tumors especially for gastrointestinal stromal tumors and metastatic renal cell carcinoma (RCC) but associated with cardiovascular toxicity.
Shi-yu Huang, Min Hu, Yu-jie Chen, Jia-chen Liu, Zhi-yuan Yao, Zhi-yuan Chen, Xiu-heng Liu, Lei Wang   +7 more
doaj   +2 more sources

Dapagliflozin May Protect Against Doxorubicin-Induced Cardiotoxicity

Anatolian Journal of Cardiology, 2023
Background: Doxorubicin is a widely used agent in the treatment of cancer, but the cardiotoxicity associated with this drug limits its potential for use.
Sebahat Ulusan, Kanat Gülle, Ahmet Peynirci, Murat Sevimli, Adnan Karaibrahimoglu, Mevlüt Serdar Kuyumcu   +5 more
doaj   +1 more source

Therapeutic effect and rebound evaluation of dapagliflozin on glycated hemoglobin (HbA1c) in type 1 diabetes mellitus patients

Frontiers in Pharmacology, 2023
Dapagliflozin has been used to treat patients with type 1 diabetes mellitus; however, the actual drug efficacy of dapagliflozin on glycated hemoglobin (HbA1c) and whether there is a rebound from dapagliflozin efficacy on HbA1c remain unknown. The present
Dong-Dong Wang, Cun Zhang, Ke Hu, Su-Mei He, Ping Zhu, Xiao Chen   +5 more
doaj   +1 more source

Dapagliflozin [PDF]

Hospital Pharmacy, 2014
Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing
Dennis J, Cada, Terri L, Levien, Danial E, Baker   +2 more
openaire   +2 more sources

Dapagliflozin, metformin, monotherapy or both in patients with metabolic syndrome

Scientific Reports, 2021
The present study evaluated the effects of dapagliflozin, a SGLT2 inhibitor, or dapagliflozin plus metformin versus metformin monotherapy in patients with metabolic syndrome.
Lan Cheng, Qianyu Fu, Longhua Zhou, Yuqin Fan, Fenfen Liu, Yuanyuan Fan, Xin Zhang, Weiqing Lin, Xiaohe Wu   +8 more
doaj   +1 more source

The Association between Dapagliflozin Use and the Risk of Post-Contrast Acute Kidney Injury in Patients with Type 2 Diabetes and Chronic Kidney Disease: A Propensity-Matched Analysis

Kidney & Blood Pressure Research, 2023
Introduction: This study aimed to investigate the effect of dapagliflozin in preventing post-contrast acute kidney injury (PC-AKI) in patients with type 2 diabetes (T2DM) and chronic kidney disease (CKD) who underwent an elective coronary procedure ...
Tao Liu, Xinwen Jian, Li Li, Shan Chu, Zeyuan Fan   +4 more
doaj   +1 more source

A Network Meta-Analysis of the Dose–Response Effects of Dapagliflozin on Efficacy and Safety in Adults With Type 1 Diabetes

Frontiers in Endocrinology, 2022
BackgroundMost patients with type 1 diabetes (T1DM) do not reach the blood glucose goal with treatment of insulin. In our research, we intended to estimate the therapeutic effect and safety of additional different doses of dapagliflozin on insulin ...
Yinhui Li, Hui Li, Liming Dong, Dandan Lin, Lijuan Xu, Pengwei Lou, Deng Zang, Kai Wang, Li Ma   +8 more
doaj   +1 more source

Sodium-Glucose Co-transporter-2 Inhibitor of Dapagliflozin Attenuates Myocardial Ischemia/Reperfusion Injury by Limiting NLRP3 Inflammasome Activation and Modulating Autophagy

Frontiers in Cardiovascular Medicine, 2022
Background: The sodium-glucose co-transporter-2 (SGLT-2) inhibitor dapagliflozin improves cardiovascular outcomes in patients with type 2 diabetes in a manner that is partially independent of its hypoglycemic effect.
Yong-Wei Yu, Yong-Wei Yu, Jia-Qun Que, Shuai Liu, Kai-Yu Huang, Lu Qian, Ying-Bei Weng, Fang-Ning Rong, Lei Wang, Ying-Ying Zhou, Yang-Jing Xue, Kang-Ting Ji   +11 more
doaj   +1 more source

Dapagliflozin Mitigated Elevated Disomic and Diploid Sperm in a Mouse Model of Diabetes and Recover the Disrupted Ogg1, Parp1, and P53 Gene Expression

Biomedicines, 2023
Increases in numerical chromosomal syndromes were observed in children of diabetic mothers. However, the effects of diabetes on male reproduction, specifically numerical chromosomal aberrations (aneuploidy), have not been studied.
Norah A. Albekairi, Mohammed A. Al-Hamamah, Ali A. Alshamrani, Mohamed S. M. Attia, Ahmed Nadeem, Mushtaq A. Ansari, Sheikh F. Ahmad, Saleh A. Bakheet, Sabry M. Attia   +8 more
doaj   +1 more source